EP3978015A4 - Anticorps bispécifique - Google Patents
Anticorps bispécifique Download PDFInfo
- Publication number
- EP3978015A4 EP3978015A4 EP20782232.1A EP20782232A EP3978015A4 EP 3978015 A4 EP3978015 A4 EP 3978015A4 EP 20782232 A EP20782232 A EP 20782232A EP 3978015 A4 EP3978015 A4 EP 3978015A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bispecific antibody
- bispecific
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019071840 | 2019-04-04 | ||
JP2020022256 | 2020-02-13 | ||
PCT/JP2020/015266 WO2020204152A1 (fr) | 2019-04-04 | 2020-04-03 | Anticorps bispécifique |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3978015A1 EP3978015A1 (fr) | 2022-04-06 |
EP3978015A4 true EP3978015A4 (fr) | 2022-12-21 |
Family
ID=72669033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20782232.1A Pending EP3978015A4 (fr) | 2019-04-04 | 2020-04-03 | Anticorps bispécifique |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220185885A1 (fr) |
EP (1) | EP3978015A4 (fr) |
JP (2) | JP7405139B2 (fr) |
KR (1) | KR20210149044A (fr) |
CN (1) | CN113660952A (fr) |
AU (1) | AU2020251578A1 (fr) |
BR (1) | BR112021019823A2 (fr) |
CA (1) | CA3136395A1 (fr) |
IL (1) | IL286918A (fr) |
MX (1) | MX2021012061A (fr) |
SG (1) | SG11202110993QA (fr) |
TW (1) | TW202102544A (fr) |
WO (1) | WO2020204152A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202340257A (zh) * | 2018-02-09 | 2023-10-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
WO2021210662A1 (fr) | 2020-04-17 | 2021-10-21 | 小野薬品工業株式会社 | Procédé d'élimination de couleur pour principe actif de formulation de protéine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106939050A (zh) * | 2017-03-27 | 2017-07-11 | 顺昊细胞生物技术(天津)股份有限公司 | 抗pd1和cd19双特异性抗体及其应用 |
WO2019009726A1 (fr) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Molécules de liaison permettant de moduler l'activité biologique exprimée par une cellule |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
EP0523949B1 (fr) | 1991-07-15 | 2003-06-25 | The Wellcome Foundation Limited | Production d'anticorps |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
ATE447617T1 (de) | 1999-04-15 | 2009-11-15 | Crucell Holland Bv | Verwendung von rekombinanten proteinen in menschlichen zellen |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
NZ519012A (en) | 2001-05-21 | 2003-10-31 | Orgapack Gmbh | Manually actuated strapping unit for wrapping a steel strap around a packaged item |
WO2003011911A1 (fr) | 2001-07-31 | 2003-02-13 | Ono Pharmaceutical Co., Ltd. | Substance specifique pour pd-1 |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
JP2004072286A (ja) | 2002-08-05 | 2004-03-04 | Nippon Telegr & Teleph Corp <Ntt> | 構造変化検出方法および通信網異常状態検出方法、並びに、その装置およびプログラム |
ES2729974T3 (es) | 2003-01-23 | 2019-11-07 | Ono Pharmaceutical Co | Anticuerpo específico de PD-1 y CD3 humanas |
JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するFc変異体 |
AU2006230413B8 (en) * | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
WO2008092117A2 (fr) * | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Nouvelles insertions, délétions et substitutions d'immunoglobulines |
SG10201605394SA (en) * | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
EP2556747B1 (fr) * | 2008-06-27 | 2020-12-02 | Merus N.V. | Souris transgéniques produisant un anticorps |
ES2893855T3 (es) | 2011-08-11 | 2022-02-10 | Ono Pharmaceutical Co | Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1 |
NZ630563A (en) | 2012-09-27 | 2017-04-28 | Merus Nv | Bispecific igg antibodies as t cell engagers |
MX2018004988A (es) * | 2015-10-23 | 2018-11-09 | Merus Nv | Moleculas de union que inhibe el crecimiento de cancer. |
WO2019070047A1 (fr) | 2017-10-06 | 2019-04-11 | 小野薬品工業株式会社 | Anticorps bispécifique |
TW202340257A (zh) | 2018-02-09 | 2023-10-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
-
2020
- 2020-04-01 TW TW109111271A patent/TW202102544A/zh unknown
- 2020-04-03 AU AU2020251578A patent/AU2020251578A1/en active Pending
- 2020-04-03 EP EP20782232.1A patent/EP3978015A4/fr active Pending
- 2020-04-03 JP JP2021512315A patent/JP7405139B2/ja active Active
- 2020-04-03 MX MX2021012061A patent/MX2021012061A/es unknown
- 2020-04-03 CN CN202080026225.8A patent/CN113660952A/zh active Pending
- 2020-04-03 SG SG11202110993QA patent/SG11202110993QA/en unknown
- 2020-04-03 WO PCT/JP2020/015266 patent/WO2020204152A1/fr unknown
- 2020-04-03 CA CA3136395A patent/CA3136395A1/fr active Pending
- 2020-04-03 BR BR112021019823A patent/BR112021019823A2/pt unknown
- 2020-04-03 KR KR1020217031140A patent/KR20210149044A/ko unknown
- 2020-04-03 US US17/601,354 patent/US20220185885A1/en active Pending
-
2021
- 2021-10-03 IL IL286918A patent/IL286918A/en unknown
-
2023
- 2023-11-24 JP JP2023198746A patent/JP2024009224A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106939050A (zh) * | 2017-03-27 | 2017-07-11 | 顺昊细胞生物技术(天津)股份有限公司 | 抗pd1和cd19双特异性抗体及其应用 |
WO2019009726A1 (fr) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Molécules de liaison permettant de moduler l'activité biologique exprimée par une cellule |
Non-Patent Citations (2)
Title |
---|
SEBASTIAN KOBOLD ET AL: "Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy", FRONTIERS IN ONCOLOGY, vol. 8, 25 July 2018 (2018-07-25), XP055587431, DOI: 10.3389/fonc.2018.00285 * |
See also references of WO2020204152A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2020251578A1 (en) | 2021-10-28 |
JP7405139B2 (ja) | 2023-12-26 |
KR20210149044A (ko) | 2021-12-08 |
SG11202110993QA (en) | 2021-11-29 |
BR112021019823A2 (pt) | 2021-12-07 |
MX2021012061A (es) | 2021-11-03 |
JPWO2020204152A1 (fr) | 2020-10-08 |
CA3136395A1 (fr) | 2020-10-08 |
WO2020204152A1 (fr) | 2020-10-08 |
CN113660952A (zh) | 2021-11-16 |
TW202102544A (zh) | 2021-01-16 |
JP2024009224A (ja) | 2024-01-19 |
US20220185885A1 (en) | 2022-06-16 |
IL286918A (en) | 2021-12-01 |
EP3978015A1 (fr) | 2022-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3903817A4 (fr) | Nouvel anticorps anti-ccr8 | |
EP3487888A4 (fr) | Anticorps anti-her2 bispécifique | |
EP3986936A4 (fr) | Anticorps anti-tigit | |
EP3941944A4 (fr) | Anticorps de claudin-6 bispécifiques | |
EP4008730A4 (fr) | Anticorps anti-ctla4-anti-pd-1 bispécifique et ses utilisations | |
EP3885367A4 (fr) | Anticorps bispécifique anti-her2/pd1 | |
EP3784699A4 (fr) | Anticorps anti-tl1a optimisés | |
EP3763743A4 (fr) | Anticorps bispécifique | |
EP3746120A4 (fr) | Anticorps anti-pd-1 | |
EP3752536A4 (fr) | Anticorps anti-her2 | |
EP3831851A4 (fr) | Anticorps anti-btla | |
EP3626745A4 (fr) | Anticorps bispécifique recombinant | |
AU2019361253A1 (en) | Anti-synuclein antibodies | |
EP3733713A4 (fr) | Anticorps bispécifique et ses applications | |
EP3768724A4 (fr) | Nouveaux anticorps anti-pd-1 | |
EP3693013A4 (fr) | Anticorps bispécifique | |
EP3995582A4 (fr) | Anticorps anti-epha4 | |
EP3986462A4 (fr) | Anticorps anti-tim-3 | |
EP3866851A4 (fr) | Anticorps bispécifiques ciblant des exosomes | |
EP3852779A4 (fr) | Anticorps anti-klrg1 | |
IL286918A (en) | Bispecific antibody | |
IL286757A (en) | Antibodies in specific | |
EP3917965A4 (fr) | Nouveaux anticorps anti-ifnar1 | |
EP3901173A4 (fr) | Protéine bispécifique | |
EP3998286A4 (fr) | Anticorps bispécifique symétrique tétravalent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211004 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20221122 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101ALI20221116BHEP Ipc: C07K 16/28 20060101AFI20221116BHEP |